All articles by GlobalData 

  1. Maintenance olaparib trial brings hope to BRCA mutant pancreatic cancer patients

    Pancreatic cancer is known to be one of the few diseases that still has a medium overall survival of less…
    Read More…

    10 Jun
  2. Gene therapy dominated haemophilia B pipeline may see long-term benefits

    Hemophilia B is an inherited deficiency in the clotting factor IX (FIX), which results in poor clotting following minor trauma…
    Read More…

    7 Jun
  3. Sanofi offers more convenient delivery in multiple myeloma treatment with Isatuximab

    One of the most exciting sessions at this year’s American Society of Clinical Oncology (ASCO) meeting last month in Chicago,…
    Read More…

    7 Jun
  4. Pfizer’s Phase III trial of Lyrica in PGTC seizures falls short of endpoint

    A Phase III study assessing the use of Lyrica (pregabalin) as adjunctive therapy for epilepsy patients ages 5 to 65…
    Read More…

    7 Jun
  5. Landmark study shows pharma worse than the automotive industry for carbon emissions

    A study published in the Journal of Cleaner Production has found the global pharma industry to be a major polluter,…
    Read More…

    6 Jun
  6. Amgen unveils promising data in KRAS G12C non-small cell lung cancer

    Amgen’s KRAS G12C inhibitor, AMG 510 has been one of the most closely watched early-phase oncology assets recently. KRAS is…
    Read More…

    6 Jun
  7. Novel biologics are on the horizon for EGFR-mutated non-small cell lung cancer

    One of the highlights of this year’s American Society of Clinical Oncology (ASCO) meeting was the emerging treatment options in…
    Read More…

    6 Jun
  8. AbbVie shoots for AAN 2020 target readout for Phase II MS trials at current enrolment rate

    AbbVie’s Phase II trials of ABT-555 (elezanumab) in various forms of multiple sclerosis (MS) has a target readout at next…
    Read More…

    6 Jun
  9. Novartis denies physicians’ reports of Mayzent launch delays

    Novartis has denied reports that the launch of Mayzent (siponimod), following its 27 March US approval in multiple sclerosis (MS)…
    Read More…

    6 Jun
  10. Long-awaited novel therapies for ovarian cancer have arrived

    Until the last decade, the treatment options for ovarian cancer have remained largely unchanged. The approval of Genentech’s Avastin (bevacizumab),…
    Read More…

    5 Jun
Close
Close
Close

Go Top